Clinical Trials Logo

White Matter Hyperintensity clinical trials

View clinical trials related to White Matter Hyperintensity.

Filter by:
  • None
  • Page 1

NCT ID: NCT05982470 Not yet recruiting - Clinical trials for Mild Cognitive Impairment

Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI

MIRACLE
Start date: August 18, 2023
Phase: Phase 2
Study type: Interventional

The objective of this clinical trial is to explore the efficacy of menopausal hormone therapy in early menopausal women with CSVD and MCI. The main questions it aims to answer are: - The efficacy of menopausal hormone mainly estrogen therapy for early menopausal women with CSVD and MCI - The role of MHT in delaying the progression of cognitive function, CSVD imaging features, and other clinical symptoms and the potential pathophysiological mechanisms. Participants will be divided randomly into two groups taking MHT drugs and placebo respectively and followed up for 12 months to collect relevant clinical data.

NCT ID: NCT05586750 Active, not recruiting - Aging Clinical Trials

Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy

STAREE-Mind
Start date: September 19, 2019
Phase: Phase 4
Study type: Interventional

The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year period, compared with placebo, on markers of brain health.

NCT ID: NCT04532697 Recruiting - Clinical trials for Mild Cognitive Impairment

Use of Gou-Teng to Treat Patients With Mild Cognitive Impairment

Start date: November 24, 2020
Phase: N/A
Study type: Interventional

Mild cognitive impairment (MCI) is a pre-dementia condition commonly occurs in elderly people. As Hong Kong has become an aged society, the prevalence of dementia and MCI in Hong Kong has increased substantially in recent decades. To date, no effective pharmacological therapies are available for MCI, and there exists a need for exploring complementary treatment for this age-related condition. Preclinical studies have identified Uncaria rhynchophylla (Gouteng in Chinese) to have promising neuroprotective effect in Alzheimer's disease experimental models. Objective: To assess the effectiveness and the safety of oral administration of Uncaria rhynchophylla for MCI in older people in Hong Kong. Study design: This is a double-blinded, randomized, placebo controlled pilot study. 56 patients with MCI will be randomized into two groups i.e. Uncaria rhynchophylla and placebo groups. All subjects will receive treatment twice a day for a consecutive 16 weeks.

NCT ID: NCT04465448 Terminated - Multiple Sclerosis Clinical Trials

Evaluation of the Reproducibility of the Measurement of the QSM Signal (Quantitative Susceptibility Mapping)

ERESI
Start date: December 17, 2020
Phase:
Study type: Observational

Many central nervous system pathologies have an inflammatory component, often associated with an accumulation of disability and more severe tissue damage. In multiple sclerosis, the inflammatory process is in part characterized by the activation of microglia, an entity of the innate inflammatory system, as well as a breakdown of the blood-brain barrier. During inflammation, activated microglia may contain high levels of iron, characterizing its activated state.